Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avidity Biosciences, Inc.

26.66
+0.90003.49%
Post-market: 26.660.00000.00%17:37 EDT
Volume:1.53M
Turnover:40.57M
Market Cap:3.20B
PE:-9.23
High:27.02
Open:25.77
Low:25.66
Close:25.76
Loading ...

Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board

GlobeNewswire
·
04 Nov 2024

Wave Life Sciences: Pioneering RNA-Editing with Promising Obesity and Cardiovascular Innovations

TIPRANKS
·
04 Nov 2024

Circio Holding ASA Strengthens Capital for RNA Therapeutics

TIPRANKS
·
01 Nov 2024

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024

PR Newswire
·
31 Oct 2024

Avidity Biosciences: Promising Developments in FSHD Treatment Justify Buy Rating

TIPRANKS
·
31 Oct 2024

BRIEF-Wave Life Sciences Plans To Have Five Galnac-RNA Editing Or GalNAc-siRNA Programs In Clinic By 2026

Reuters
·
31 Oct 2024

Wave Life Sciences Expands RNA Therapeutic Pipeline

TIPRANKS
·
31 Oct 2024

Avidity Biosciences: Strategic Advances and Promising Progress Justify Buy Rating

TIPRANKS
·
30 Oct 2024

Avidity Biosciences Is Maintained at Buy by Chardan Capital

Dow Jones
·
30 Oct 2024

Avidity Biosciences price target raised to $65 from $60 at Chardan

TIPRANKS
·
30 Oct 2024

BRIEF-Avidity Biosciences Pursues Potential Accelerated Approval Path With Initiation Of Biomarker Cohort In FORTITUDE Trial For Delpacibart Braxlosiran (del-brax/AOC 1020) In People Living With Facioscapulohumeral Muscular Dystrophy

Reuters
·
30 Oct 2024

Avidity Biosciences: Enrollment in Del-Brax Biomarker Cohort Expected to Be Completed in 1H 2025

THOMSON REUTERS
·
30 Oct 2024

Avidity Biosciences Pursues Potential Accelerated Approval Path With Initiation of Biomarker Cohort in Fortitude™ Trial for Delpacibart Braxlosiran (Del-Brax/Aoc 1020) in People Living With Facioscapulohumeral Muscular Dystrophy

THOMSON REUTERS
·
30 Oct 2024

Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy

PR Newswire
·
30 Oct 2024

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

GlobeNewswire
·
26 Oct 2024

Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting

GlobeNewswire
·
25 Oct 2024

Circio Holding ASA Unveils Breakthrough in Gene Therapy

TIPRANKS
·
25 Oct 2024

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

GlobeNewswire
·
23 Oct 2024

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
22 Oct 2024

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire
·
22 Oct 2024